Inclusion Criteria:  Be female Be diagnosed with cervical, vaginal or vulvar cancer Be at least 18 years of age If of child-bearing potential, must have a negative pregnancy test Be able to comply with study procedures Have read and signed the Institutional Review Board (IRB)-approved informed consent form for participating in the study  Exclusion Criteria:  Females who are pregnant or nursing Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 hours afterwards  Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example:  Patients on life support or in a critical care unit Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia Patients with recent cerebral hemorrhage Patients who have undergone surgery within 24 hours prior to the study sonographic examination Patients with congenital heart defects Patient with a known allergy to Sonazoid (including an anaphylactic allergy to eggs or egg products)